IL164031A - Compositiion having gelling properaties for the prolonged delivery of bioactive substances - Google Patents

Compositiion having gelling properaties for the prolonged delivery of bioactive substances

Info

Publication number
IL164031A
IL164031A IL164031A IL16403104A IL164031A IL 164031 A IL164031 A IL 164031A IL 164031 A IL164031 A IL 164031A IL 16403104 A IL16403104 A IL 16403104A IL 164031 A IL164031 A IL 164031A
Authority
IL
Israel
Prior art keywords
properaties
compositiion
gelling
bioactive substances
prolonged delivery
Prior art date
Application number
IL164031A
Other languages
English (en)
Original Assignee
Ethypharm Sa
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0203059A external-priority patent/FR2837099B1/fr
Application filed by Ethypharm Sa, Univ Montreal filed Critical Ethypharm Sa
Publication of IL164031A publication Critical patent/IL164031A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL164031A 2002-03-12 2004-09-12 Compositiion having gelling properaties for the prolonged delivery of bioactive substances IL164031A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0203059A FR2837099B1 (fr) 2002-03-12 2002-03-12 Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
US40572002P 2002-08-26 2002-08-26
PCT/FR2003/000797 WO2003075885A1 (fr) 2002-03-12 2003-03-12 Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives

Publications (1)

Publication Number Publication Date
IL164031A true IL164031A (en) 2010-11-30

Family

ID=27806677

Family Applications (1)

Application Number Title Priority Date Filing Date
IL164031A IL164031A (en) 2002-03-12 2004-09-12 Compositiion having gelling properaties for the prolonged delivery of bioactive substances

Country Status (12)

Country Link
US (1) US7691408B2 (pt)
EP (1) EP1485066B1 (pt)
JP (1) JP2005528352A (pt)
CN (1) CN100584314C (pt)
AU (1) AU2003227827B2 (pt)
BR (1) BRPI0308360B8 (pt)
CA (1) CA2478825C (pt)
IL (1) IL164031A (pt)
MX (1) MXPA04008906A (pt)
NO (1) NO339426B1 (pt)
NZ (1) NZ535270A (pt)
WO (1) WO2003075885A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535270A (en) 2002-03-12 2006-11-30 Univ Montreal Composition having gelling properties for the sustained delivery of bioactive substances
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PL1891862T3 (pl) * 2006-07-24 2012-08-31 Unilever Nv Prekursor napoju
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
FR2926996B1 (fr) * 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
NZ607103A (en) * 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
EP2425814B1 (en) * 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
CN108479649A (zh) * 2018-05-10 2018-09-04 哈尔滨工业大学 一种有机凝胶的制备方法与应用
CN118201599A (zh) * 2021-12-24 2024-06-14 四川科伦药物研究院有限公司 一种可平稳释放的持续性递送制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
US3969087A (en) 1974-08-07 1976-07-13 Ajinomoto Co., Ltd. Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents
JPS5119139A (ja) * 1974-08-07 1976-02-16 Ajinomoto Kk Gerujokeshoryososeibutsu
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
CN1079658C (zh) * 1993-10-18 2002-02-27 普罗克特和甘保尔公司 不发汗唇膏
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6306383B1 (en) 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
FR2794998B1 (fr) * 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques
FR2795360B1 (fr) 1999-06-24 2001-12-14 Technologique De Prec Mecaniqu Procede de fabrication d'articles de conditionnement et machine de fabrication correspondante
NZ535270A (en) 2002-03-12 2006-11-30 Univ Montreal Composition having gelling properties for the sustained delivery of bioactive substances

Also Published As

Publication number Publication date
NZ535270A (en) 2006-11-30
EP1485066A1 (fr) 2004-12-15
NO339426B1 (no) 2016-12-12
BR0308360A (pt) 2005-01-25
CA2478825A1 (fr) 2003-09-18
CN1649567A (zh) 2005-08-03
HK1071704A1 (zh) 2005-07-29
JP2005528352A (ja) 2005-09-22
EP1485066B1 (fr) 2016-09-21
BR0308360B1 (pt) 2017-11-14
MXPA04008906A (es) 2005-09-08
US7691408B2 (en) 2010-04-06
AU2003227827A1 (en) 2003-09-22
WO2003075885A1 (fr) 2003-09-18
US20060121115A1 (en) 2006-06-08
CA2478825C (fr) 2012-01-24
NO20044310L (no) 2004-10-12
AU2003227827B2 (en) 2008-09-25
BRPI0308360B8 (pt) 2021-05-25
CN100584314C (zh) 2010-01-27

Similar Documents

Publication Publication Date Title
AU2003222137A1 (en) Microgel particles for the delivery of bioactive materials
GB2391480B (en) Drug delivery system
GB0310300D0 (en) Nanocomposite drug delivery composition
AU2003291103A8 (en) Pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
PL376169A1 (en) Drug delivery system
AU2003250372A8 (en) Pharmaceutical composition
SG118275A1 (en) Polymers for the delivery of bioactive agents and methods of their preparation
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
PL370162A1 (en) Orodispersible pharmaceutical composition comprising perindopril
AU2003296961A8 (en) Targeted invitation delivery
PL373409A1 (en) Pharmaceutical combination
IL164031A0 (en) Composition having gelling properaties for the prolonged delivery of bioactive substances
GB0327814D0 (en) Aerosolisable composition and delivery system
PL379424A1 (pl) Nowe układy dostarczania gumy
GB0225827D0 (en) Medicated comestibles
GB0217703D0 (en) Pharmaceutical composition
EP1547593A4 (en) MEDICINAL COMPOSITION
GB0217478D0 (en) Multiple-therapy drug delivery
GB0209411D0 (en) Drug delivery
GB0212738D0 (en) Microspheres for bioactive delivery
SI1467750T1 (sl) Farmacevtski sestavek perindoprila disperzen v ustih (orodisperzen)
GB0219421D0 (en) Improvements in or relating to formulations for the delivery of drugs
GB0210238D0 (en) Pharmaceutical composition
GB0214491D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees